Fragile X Syndrome Clinical Trials

Find Fragile X Syndrome Clinical Trials Near You

The Neurocognitive Bases of Trust in Intellectual Disability: Affective Evaluation, Trait Attribution, and Epistemic Vigilance

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

This project studies the neurocognitive basis of trust adjustment in intellectual disability (ID), a source of significant vulnerability for these patients, focusing on two target populations chosen for their specific social characteristics: people with Down syndrome, who are often described as being hypersocial, and people with Fragile X syndrome, who are often characterized by a completely opposite social behaviour profile, with a withdrawn attitude and significant social anxiety. The three different types of mechanisms that contribute to the adjustment of interpersonal trust: affective evaluation, trait attribution, and epistemic evaluation of informants, will be studied. Affective evaluation processes recruit subcortical structures such as the amygdala and assess potential social threats in the environment. The second mechanism for selecting whom to trust consists of forming a representation of a person's dispositions, such as benevolence and competence (also known as traits), and using it to predict that person's future behaviour. Trait attribution processes recruit a cortico-cerebellar network comprising the mPFC, CRUS I and posterior lobule VI. The third mechanism, called epistemic vigilance, allows to adjust our trust in what others communicate to us. This mechanism involves linking the assessment of the reliability of individuals who communicate (based on their benevolence and competence) with the reliability of the communicated information. Epistemic assessment involves frontal areas and areas associated with the representation of mental states in order to enable the evaluation of the truthfulness of the communicated information. All of these mechanisms become functional very early on, before a child's sixth birthday. There are reasons to expect that several of these central mechanisms supporting selective trust will behave atypically in intellectual disability.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 3
Maximum Age: 29
Healthy Volunteers: t
View:

⁃ Group of Down Syndrom patients

• Complete chromosomal trisomy of the 21st chromosome confirmed by karyotype analysis

• Aged 13 to 29 (chronological age)

• French as their native language

• Having signed an informed consent form and/or whose legal guardians/patient representatives have signed the informed consent form

• Affiliated with the French health insurance system (social security) or whose legal guardians are affiliated with the French health insurance system

⁃ Group of X-Fragile Syndrome

• Complete mutation of the FMR1 gene by molecular analysis (more than 200 CGG triplet repeats)

• Aged between 13 and 29 (chronological age)

• Native French speakers

• Having signed an informed consent form and/or whose legal guardians/patient representatives have signed the informed consent form

• Affiliated with the French health insurance system (social security) or whose legal guardians are affiliated with the French health insurance system

⁃ Group of chronological age-matched control

• Aged between 13 and 29

• Native French speakers.

• Having signed an informed consent form and/or whose legal guardians/patient representatives have signed the informed consent form

• Affiliated with the French health insurance system (social security) or whose legal guardians are affiliated with the French health insurance system

⁃ Group of mental age-matched control

• Aged between 3 and 9

• Native French speakers.

• Whose legal guardians/patient representatives have signed the informed consent form

• Affiliated with the French health insurance system (social security) or whose legal guardians are affiliated with the French health insurance system

Locations
Other Locations
France
Reference Center of Rare Disease with Intellectual Disability in Lyon, Woman Mother and Child Hospital, University Hospital of Lyon, Hospices Civils de Lyon
RECRUITING
Bron
Contact Information
Primary
CURIE MD AURORE, MD
Aurore.curie@chu-lyon.fr
+33 (0)6.70.62.69.76
Time Frame
Start Date: 2026-07-17
Estimated Completion Date: 2030-01
Participants
Target number of participants: 112
Treatments
Down Syndrome patients
Patients aged 13 to 29 years old with a confirmed diagnosis of Down Syndrome
Fragile X Syndrome patients
Patients aged 13 to 29 years old with a confirmed diagnosis of Fragile X Syndrome
Chronological age-matched controls
Persons aged 13 to 29 years old with typical development
Mental age-matched controls
Persons aged 3 to 9 years old with typical development
Sponsors
Leads: Hospices Civils de Lyon

This content was sourced from clinicaltrials.gov

Similar Clinical Trials